Glioblastoma Multiforme

Caregiver Mastery Linked to Patient Survival in Glioblastoma

Caregiver Mastery Linked to Patient Survival in Glioblastoma

By

An analysis of data from caregivers and patients participating in a longitudinal study funded by the National Institutes of Health examines whether caregivers' anxiety, depressive symptoms, burden, and mastery influence survival for patients with newly diagnosed glioblastoma multiforme.

Medicaid Insurance Linked to Worse Outcomes for Patients With Glioblastoma Multiforme

Medicaid Insurance Linked to Worse Outcomes for Patients With Glioblastoma Multiforme

By

Insurance status influences overall patient survival for some cancer types, but its impact on glioblastoma multiforme (GBM) survival is well documented. This research study explored the possible impact of insurance on GBM survival.

Extent of Resection Influences Length of Progression-Free Survival in Glioblastoma

Extent of Resection Influences Length of Progression-Free Survival in Glioblastoma

By

Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Discovery might eventually lead to better treatment for glioblastoma multiforme

Valproic Acid, Levetiracetam Do Not Improve Survival in Newly Diagnosed GBM

By

Valproic acid and levetiracetam do not improve survival outcomes in patients with newly diagnosed glioblastoma, according to a recently published study.

Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme

Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme

By

Researchers identified propentofylline as a drug that could help treat patients with the deadly brain cancer glioblastoma multiforme.

Low-grade brain tumor diagnosis redefined

By

A tumor's DNA composition plays a key role in whether a glioma may transform into a more serious glioblastoma.

Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma

Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma

Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.

Targeting a unique receptor promising for glioblastoma multiforme

By

Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.

Autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.

Optimal dosing for TMZ: 1 hour prior to RT versus bedtime

Optimal dosing for TMZ: 1 hour prior to RT versus bedtime

By

Is there a difference in dosing (1 hour prior to radiotherapy vs bedtime) with temozolomide plus radiotherapy for glioblastoma multiforme?

Lightwaves improve brain tumor surgery

By

First-of-its-kind research shows promise for developing a method to clearly identify cancerous tissue during surgery. These findings may potentially improve outcomes for those undergoing surgery to remove glioblastoma multiforme.

Cancer stem cells targeted in malignant brain tumors

By

Researchers have also created an experimental vaccine to attack immune system targets related to cancer stem cells, the cells from which malignant brain tumors are believed to originate and regenerate.

Personalized vaccine for most lethal type of brain tumor shows promise

Personalized vaccine for most lethal type of brain tumor shows promise

By

Patients with recurrent GBM treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine.

Inflammatory protein converts glioblastoma cells into the most aggressive version

By

A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy.

Early poliovirus vaccine trial promising for recurrent glioblastoma

By

Attacking glioblastoma brain tumor cells with a modified poliovirus is showing encouraging early results in an ongoing study.

Dasatinib thwarts brain cancer metastasis after bevacizumab use

Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.

5-ALA fluorescence guide improves resection of glioblastoma multiforme

By

Fluorescence form 5-aminolevulinic acid (5-ALA) has been used to guide resection of recurrent GBM. Before surgery, the patient ingests 5-ALA, then the tumor cells fluoresce intraoperatively in response to certain wavelengths of light.

ELTD1 protein may be new biomarker for glioma

ELTD1, a protein linked with angiogenesis, is the strongest candidate for a significant association with glioma out of nearly 200 possible markers.

Smaller radiation fields can spare brain when treating tumors

By

Patients with aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.

Aggressive brain tumors can originate from a range of nervous system cells

By

Glioblastoma multiforme tumors can originate not only from the glial cells that make up the supportive tissue of the brain and from neural stem cells, but also from other types of differentiated cells in the nervous system, including cortical neurons.

Short-term fasting enhances brain tumor treatment

A controlled fasting period lasting no more than 48 hours improved the effectiveness of chemotherapy and radiation therapy in mice with gliomas.

Multiple tumors worsen glioblastoma prognosis

Persons with more than one glioblastoma tumor upon diagnosis experience significantly worse survival than do patients with a solitary lesion.

Stem-like cells help glioblastoma defy treatment

A slower-growing set of glioblastoma multiforme cells appears to be the source of the brain cancer's recurrence following standard drug therapy.

VEGF blockade: Optimizing chemotherapy drug uptake

VEGF blockade: Optimizing chemotherapy drug uptake

By

New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.

Enzyme inhibition may brighten glioma treatment outlook

Medications were able to block a newly identified cancer-promoting pathway and delay glioma growth in mice, suggesting a new treatment option to combat malignant glioma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs